Risk of Progression Independent of Relapse Activity and Disability Accumulation in a Real-world Cohort of Multiple Sclerosis Patients Initiated on High-efficacy Versus Low-efficacy Disease Modifying Therapy

Idiosyncratic Drug–induced Neutropenia Secondary to Ofatumumab Exposure in Multiple Sclerosis: A Case Report and Analysis of Food and Drug Administration Adverse Event Reporting System